Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO 63110, USA.
Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
Trends Cell Biol. 2019 Sep;29(9):740-751. doi: 10.1016/j.tcb.2019.06.005. Epub 2019 Jul 27.
The concept of 'BRCAness' defines the pathogenesis and vulnerability of multiple cancers. The canonical definition of BRCAness is a defect in homologous recombination repair, mimicking BRCA1 or BRCA2 loss. In turn, BRCA-deficient cells utilize error-prone DNA-repair pathways, causing increased genomic instability, which may be responsible for their sensitivity to DNA damaging agents and poly-(ADP)-ribose polymerase inhibitors (PARPis). However, recent work has expanded the mechanistic basis of BRCAness, to include defects in replication fork protection (RFP). Here, we broaden the definition of BRCAness to include RFP and regulatory mechanisms that cause synthetic lethality with PARPis. We highlight these recent discoveries, which include mechanisms of RFP regulation, DNA damage checkpoint proteins, as well as kinases that regulate BRCA1/2 function. Importantly, many of these emerging mechanisms may be targeted for inhibition with small molecule inhibitors, thus inducing BRCAness in a much larger subset of BRCA-proficient tumors, with significant translational potential.
“BRCA 样特征”的概念定义了多种癌症的发病机制和易感性。BRCA 样特征的典型定义是同源重组修复缺陷,类似于 BRCA1 或 BRCA2 的缺失。反过来,BRCA 缺陷细胞利用易错的 DNA 修复途径,导致基因组不稳定性增加,这可能是它们对 DNA 损伤剂和聚(ADP-核糖)聚合酶抑制剂(PARPi)敏感的原因。然而,最近的研究扩展了 BRCA 样特征的机制基础,包括复制叉保护(RFP)缺陷。在这里,我们将 BRCA 样特征的定义扩展到包括 RFP 和导致与 PARPi 合成致死的调节机制。我们强调了这些最近的发现,包括 RFP 调节机制、DNA 损伤检查点蛋白以及调节 BRCA1/2 功能的激酶。重要的是,这些新出现的机制中的许多可能可以用小分子抑制剂来抑制,从而在更大比例的 BRCA 功能正常的肿瘤中诱导出 BRCA 样特征,具有重要的转化潜力。